Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person ERBB2 KD mutants bind TKIs

Class:Id	Reaction:9665121
_displayName	ERBB2 KD mutants bind TKIs
_doRelease	TRUE
_timestamp	2019-11-12 18:14:42
authored	[InstanceEdit:9656339] Orlic-Milacic, Marija, 2019-07-31
compartment	[Compartment:70101] cytosol [Compartment:876] plasma membrane
created	[InstanceEdit:9665122] Orlic-Milacic, Marija, 2019-10-30
disease	[Disease:1500689] cancer
edited	[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
input	[Complex:9665141] ERBB2 KD mutants (TKI sensitive):ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens] [DefinedSet:9665127] TKIs (ERBB2) [cytosol]
isChimeric	FALSE
literatureReference	[LiteratureReference:9646435] Activating HER2 mutations in HER2 gene amplification negative breast cancer [LiteratureReference:9649397] Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib [LiteratureReference:9649445] High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2 [LiteratureReference:9646776] EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation [LiteratureReference:9647026] An Acquired HER2^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer [LiteratureReference:9646962] Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity [LiteratureReference:9646964] Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor [LiteratureReference:9650832] Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations [LiteratureReference:9650849] Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations [LiteratureReference:9665657] The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
modified	[InstanceEdit:9665159] Orlic-Milacic, Marija, 2019-10-30 [InstanceEdit:9665162] Orlic-Milacic, Marija, 2019-10-30 [InstanceEdit:9665668] Orlic-Milacic, Marija, 2019-10-31 [InstanceEdit:9666039] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666040] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666041] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666042] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666684] Orlic-Milacic, Marija, 2019-11-05 [InstanceEdit:9667512] Orlic-Milacic, Marija, 2019-11-12 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	ERBB2 KD mutants bind TKIs
output	[Complex:9665144] ERBB2 KD mutants:TKIs:ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens]
releaseDate	2019-12-10
reviewed	[InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9665123] R-HSA-9665121.2
summation	[Summation:9665160] Sensitivity to different tyrosine kinase inhibitors varies a...
(hasEvent)	[Pathway:9664565] Signaling by ERBB2 KD Mutants [Homo sapiens]
(updatedInstance)	[_UpdateTracker:9835730] Update Tracker - [Reaction:9665121] ERBB2 KD mutants bind TKIs - v85:[modifyText]
[Change default viewing format]

No pathways have been reviewed or authored by ERBB2 KD mutants bind TKIs (9665121)